| scholarly article | Q13442814 |
| P50 | author | Karen H. Lu | Q117217757 |
| David Gershenson | Q57167281 | ||
| Anais Malpica | Q69964105 | ||
| P2093 | author name string | Russell Broaddus | |
| Angela Thornton | |||
| Diane C Bodurka | |||
| Charlotte Sun | |||
| Rosemarie E Schmandt | |||
| Hyun Shvartsman | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Mechanism of action and in vivo role of platelet-derived growth factor | Q22010594 | ||
| The protein tyrosine kinase family of the human genome | Q28140214 | ||
| Oncogenic kinase signalling | Q28189493 | ||
| Cancer statistics, 2002 | Q28216788 | ||
| Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors | Q29618610 | ||
| Abl expression in human fetal and adult tissues, tumours, and tumour microvessels | Q74016833 | ||
| Surgical management of ovarian cancer | Q77628756 | ||
| Germ cell specific expression of c-kit in the human fetal gonad | Q30702708 | ||
| Signaling pathways activated by oncogenic forms of Abl tyrosine kinase | Q33663180 | ||
| Roles of KIT and KIT LIGAND in ovarian function | Q34046082 | ||
| Development of inhibitors for protein tyrosine kinases | Q34103669 | ||
| Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug | Q34139151 | ||
| Developmental roles of platelet-derived growth factors | Q34269318 | ||
| Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options | Q34461485 | ||
| Platelet-derived growth factor receptors: a therapeutic target in solid tumors | Q34461490 | ||
| Abl: mechanisms of regulation and activation. | Q34486259 | ||
| Rational therapeutic intervention in cancer: kinases as drug targets | Q34493200 | ||
| Receptor tyrosine kinases as targets for anticancer drugs | Q34498182 | ||
| Recent advancements in the treatment of chronic myelogenous leukemia | Q34511570 | ||
| Future directions in the treatment of ovarian cancer | Q34526703 | ||
| An overview of translocation-related oncogenesis in the chronic myeloid leukaemias | Q34580125 | ||
| STI571 (Gleevec) as a paradigm for cancer therapy | Q34583847 | ||
| Epithelial ovarian cancer | Q34677827 | ||
| Current clinical practices for ovarian cancers | Q34705360 | ||
| Smart drugs: tyrosine kinase inhibitors in cancer therapy | Q34710595 | ||
| The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer | Q34790551 | ||
| Protein kinases as targets for anticancer agents: from inhibitors to useful drugs | Q34792836 | ||
| Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis | Q34826546 | ||
| Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease | Q34826559 | ||
| The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). | Q34989623 | ||
| Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosis | Q35789048 | ||
| PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors | Q36234340 | ||
| The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium | Q41000835 | ||
| Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo | Q41482318 | ||
| Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders | Q47614258 | ||
| Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-beta) in human gliomas. | Q55476076 | ||
| Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer | Q73811149 | ||
| Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis | Q73911390 | ||
| Autocrine interactions of keratinocyte growth factor, hepatocyte growth factor, and kit-ligand in the regulation of normal ovarian surface epithelial cells | Q73941835 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | serous carcinoma | Q7455058 |
| ovarian serous carcinoma | Q18553575 | ||
| P304 | page(s) | 758-764 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium | |
| P478 | volume | 98 |
| Q35609644 | (124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo. |
| Q90310096 | A novel c-Kit/phospho-prohibitin axis enhances ovarian cancer stemness and chemoresistance via Notch3-PBX1 and β-catenin-ABCG2 signaling |
| Q38067438 | A practical approach to immunohistochemical diagnosis of ovarian germ cell tumours and sex cord-stromal tumours |
| Q60673301 | A prospective analysis of imatinib-induced c-kit modulation in ovarian cancer |
| Q36443421 | Activation of abl family kinases in solid tumors |
| Q30429122 | Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial |
| Q44195449 | Analysis of genomic mutation and immunohistochemistry of platelet-derived growth factor receptors in canine vascular tumours |
| Q40343201 | Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. |
| Q81311229 | Bovine papillomavirus E5 oncoprotein binds to the activated form of the platelet-derived growth factor beta receptor in naturally occurring bovine urinary bladder tumours |
| Q34473048 | CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients |
| Q37016233 | CD117 expression in operable oesophageal squamous cell carcinomas predicts worse clinical outcome |
| Q38505379 | Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. |
| Q37688839 | Coordination of signalling networks and tumorigenic properties by ABL in glioblastoma cells |
| Q41135676 | Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients. |
| Q34427424 | Establishment of an orthotopic transplantation tumor model in nude mice using a drug-resistant human ovarian cancer cell line with a high expression of c-Kit |
| Q37323849 | Expression and mutational analysis of c-kit in ovarian surface epithelial tumors |
| Q46628435 | Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications |
| Q46598906 | Expression of KIT (CD117) in renal cell carcinoma and renal oncocytoma |
| Q42180765 | Expression of c-Kit and PDGFRα in epithelial ovarian tumors and tumor stroma |
| Q46585276 | Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors |
| Q45181410 | Expression of c-kit in uterine carcinosarcoma |
| Q45072363 | Expression of imatinib mesylate-targeted kinases in endometrial carcinoma |
| Q80209901 | Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors |
| Q36695240 | Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma |
| Q53560094 | Germline stem cells and neo-oogenesis in the adult human ovary. |
| Q36046233 | Imatinib mesylate and its potential implications for gynecologic cancers |
| Q46489542 | Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. |
| Q38442025 | Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study |
| Q36289382 | Immunohistochemical expression of platelet-derived growth factor receptors in ovarian cancer patients with long-term follow-up. |
| Q53548885 | Immunohistochemistry for CD117 (KIT) is effective in distinguishing cutaneous adnexal tumors with apocrine/eccrine or sebaceous differentiation from other epithelial tumors of the skin. |
| Q47146356 | Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients. |
| Q36284514 | Investigational agents for epithelial ovarian cancer |
| Q45243753 | Kit (CD117) immunoreactivity is rare in renal cell and upper urinary tract transitional cell carcinomas |
| Q35968752 | Novel agents in epithelial ovarian cancer |
| Q46791717 | Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. |
| Q83566218 | Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube |
| Q90482324 | Pregnancy Outcomes in Chronic Myeloid Leukemia: A Single Center Experience |
| Q51060775 | Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. |
| Q36665179 | Role of the microenvironment in ovarian cancer stem cell maintenance |
| Q36953366 | Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress |
| Q37082789 | Targeting signaling pathways in ovarian cancer. |
| Q54777583 | The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. |
| Q40213329 | The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. |
| Q28282889 | The promise and perils of 'targeted therapy' of advanced ovarian cancer |
| Q39314503 | c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling. |
| Q43153201 | c-kit (CD117) expression in human tumors and its prognostic value: an immunohistochemical analysis |
Search more.